Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Annexon, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ANNX
Nasdaq
2830
www.annexonbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Annexon, Inc.
With Annexon Up 14%, Insider Buyers Count Their Returns
- Dec 11th, 2025 10:52 am
Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement
- Nov 28th, 2025 11:26 pm
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
- Nov 14th, 2025 2:01 pm
Exploring 3 High Growth Tech Stocks In The US Market
- Nov 14th, 2025 10:38 am
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
- Nov 12th, 2025 8:55 pm
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Nov 12th, 2025 2:12 pm
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
- Nov 10th, 2025 2:05 pm
Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition
- Sep 30th, 2025 9:41 am
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
- Sep 7th, 2025 8:18 am
Annexon Biosciences to Participate in Upcoming September Investor Conferences
- Aug 27th, 2025 6:00 am
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- Aug 18th, 2025 2:05 pm
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
- Aug 14th, 2025 2:05 pm
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
- Aug 7th, 2025 2:30 pm
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
- Jul 24th, 2025 5:00 am
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
- Jun 18th, 2025 2:05 pm
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
- May 29th, 2025 2:05 pm
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
- May 19th, 2025 2:05 pm
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- May 16th, 2025 2:05 pm
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
- May 12th, 2025 6:00 am
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
- May 9th, 2025 3:00 pm
Scroll